IRCT20110425006280N12
Recruiting
N/A
Evaluation of Hemoperfusion effect in treatment of patients with COVID-19 hospitalized in intensive care unit, Randomized clinical trial
Vice President of Research Guilan university of medical sciences0 sites20 target enrollmentTBD
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Vice President of Research Guilan university of medical sciences
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with a clinical diagnosis of Covid\-19 including respiratory distress with a rate of more than 30 per minute and heart rate more than 125 beats per minute and shortness of breath and oxygen saturation less than 90%, despite receiving oxygen with a positive PCR test and Radiographs in CT SCANING or Chest X Ray, admitted to the intensive care unit.
- •Uncontrollable fevers like T\> 39 C.
- •An laboratory evidence of increased inflammatory factors
- •Patients 12 years and older
- •Evidence of severe hemodynamic disturbance using moderate doses of norepinephrine or using a second dose of vasopressor
- •Involvement of more than two vital organs (lungs, kidneys, liver, and heart)
Exclusion Criteria
- •Thrombocytopenia (Plt \=20,000\)
- •Acute crisis due to sickle cell anemia
- •Evidence of resin sensitivity
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Hemoperfusion in Covid 19IRCT20210718051922N1Shahre-kord University of Medical Sciences60
Recruiting
Phase 2
The role of hemoperfusion in COVID-19COVID-19.COVID-19U07.1IRCT20200608047686N2Shahid Beheshti University of Medical Sciences40
Recruiting
N/A
Efficacy of the Hemoperfusion Therapy in Patients with Severe COVID-19-Associated Pneumonia: An Experience from Single-center Observational StudySevere COVID-19-associated pneumonia with or without hemoperfusion therapyHemoperfusion, adsorption therapy, COVID-19, Pneumonia, Acute respiratory distress syndrome, Critical care, SARS-CoV2, cytokine storm, blood purificationTCTR20210627002Faculty of Medicine, Chiang Mai University15
Completed
Phase 2
Hemoperfusion in patients with COVID-19IRCT20150704023055N2Babol University of Medical Sciences10
Completed
N/A
Clinical research for hemoperfusion therapy with an immobilized polymyxin B (PMX) fiber column in patients with severe influenza pneumonia in Vietnam and Japasevere influenza pneumoniaJPRN-UMIN000003669Disease Control and Prevention Center10